Delivery Order SPE2DB24D2217-SPE2DB25FJXTY
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a contract ceiling value of $3,874.25. This is a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $11,629.29 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This firm fixed-price contract was competitively awarded without set-aside designation and carries an ultimate completion date of September 8, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which is valued at...
- The Defense Logistics Agency awarded a delivery order valued at $2,119.21 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This is a firm fixed-price, competitively awarded delivery order with an ultimate completion date of July 22, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency (DLA) awarded a $2,248.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a $7,277.81 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 MG tablets (30-count units) with an ultimate completion date of September 12, 2025. This non-set-aside competitive award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,882.56 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This is a firm fixed price delivery order with no set-aside designation, competitively awarded and completed on August 8, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron ODT 4 MG tablets (30-count) with a contract ceiling value of $1,512.72. This firm fixed price delivery order, which is set to be completed by August 5, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The award was competitively...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,636.06 for Ondansetron ODT 8 mg tablets (30-count supply) on July 29, 2025, with completion expected by July 30, 2025. This firm fixed-price, competitively awarded contract (no set-aside used) represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is located at the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $5,709.71 and an ultimate completion date of August 25, 2025. The contract represents a non-competitive set-aside procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $2,579.06. The award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a competitively awarded non-set-aside transaction. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB24D2217Indefinite Delivery Contract
- SPE2DB24D2217-SPE2DB25FJXTYDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $2,221.53. This competitive award, issued with no set-aside designation, represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a comprehensive portfolio of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The company's broader contract awards with DLA demonstrate its capability to deliver an extensive range of therapeutics across multiple domains, from specialty medications and brand-name drugs to vaccines and medical devices. This delivery order for ondansetron, an antiemetic commonly used in medical settings, exemplifies the company's role in fulfilling routine pharmaceutical supply requirements for federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 9/16/25 |